Richard Whitley - Gilead Sciences Independent Director

<div class='circular--portrait' style='background:#FF6600;color: #FFFAFA;font-size:4em;padding-top: 25px;;'>GS</div>
GILD -- USA Stock  

Fiscal Quarter End: 30th of June 2020  

  Director
Dr. Richard James Whitley, M.D., is an Independent Director of Gilead Sciences Inc. Dr. Whitley is the Distinguished Professor, Loeb Scholar Chair in Pediatrics, and Professor of Pediatrics, Microbiology, Medicine and Neurosurgery at the University of Alabama at Birmingham. He is the CoDirector, Division of Pediatric Infectious Diseases ViceChair, Department of Pediatrics Senior Scientist, Department of Gene Therapy Director for Drug Discovery and Development and Associate Director, Comprehensive Cancer Center and CoFounder and CoDirector, Alabama Drug Discovery Alliance. Dr. Whitley is responsible for the National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group, and directs a center for drug discovery in the arena of emerging infections. He is a past President of the International Society of Antiviral Research and the Infectious Diseases Society of America, and currently chairs both the NIAID Recombinant DNA Advisory Council and the NIAID HIV Vaccine Data Safety and Management Board. He is an elected member of the American Society of Clinical Investigation, the Association of American Physicians and an Honorary member of the Irish Academy of Science.
Age: 72  Director Since 2008      
650 574-3000  www.gilead.com

Richard Whitley Latest Insider Activity

Gilead Sciences Management Efficiency

Gilead Sciences has return on total asset (ROA) of 0.0013 % which means that it generated profit of $0.0013 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of 0.0034 % meaning that it created $0.0034 on every $100 dollars invested by stockholders. Gilead Sciences management efficiency ratios could be used to measure of how well the company is managing its routine affairs as well as how well it utilizes its assets and manages liabilities. The current year Return on Investment is expected to grow to 9.18. The current year Return on Average Assets is expected to grow to 0.09Gilead Sciences Total Assets Per Share are expected to significantly increase based on the last few years of reporting. The last year's Total Assets Per Share were at 48.68. The current year Asset Turnover is expected to grow to 0.43, whereas Current Assets are expected to decline to about 1.2 B. The current year Tax Liabilities is expected to grow to about 6.6 B, whereas Total Liabilities is expected to decline to about 33.2 B.
The company currently holds 28.84 B in liabilities with Debt to Equity (D/E) ratio of 139.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Gilead Sciences has Current Ratio of 3.0 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Showing few of many executives

DIRECTOR Since

Dinesh PaliwalBristol Myers Squibb
2013
Patricia RussoMerck Company
1995
Ronald WilliamsJohnson Johnson
2011
Leslie BrunMerck Company
2016
Simon DingemansGlaxoSmithKline PLC
2011
Thomas LynchGW Pharmaceuticals Plc
2010
JeanPhilippe CourtoisAstrazeneca PLC
2008
Stephanie BurnsGlaxoSmithKline PLC
2007
Christopher ToveyGW Pharmaceuticals Plc
2012
Vindi BangaGlaxoSmithKline PLC
2017
Elizabeth DohertyNovartis AG
2016
Peter ArduiniBristol Myers Squibb
2016
Wendell WeeksMerck Company
2004
Jackson TaiEli Lilly And
2013
Laurie GlimcherGlaxoSmithKline PLC
2017
Belen MorenesGrifols S A
2013
Nancy AndrewsNovartis AG
2015
Manvinder BangaGlaxoSmithKline PLC
2016
Jennifer DoudnaJohnson Johnson
2018
Thomas GlanzmannGrifols S A
2017
William HarrisonMerck Company
2009

Company Summary

Gilead Sciences, Inc., a research-based biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical needs in the United States, Europe, and internationally. The company was founded in 1987 and is headquartered in Foster City, California. Gilead Sciences operates under Drug ManufacturersGeneral classification in USA and is traded on BATS Exchange. It employs 11800 people.Gilead Sciences (GILD) is traded on BATS Exchange in USA. It is located in 333 Lakeside Drive, Foster City, CA 94404, United States and employs 11,800 people. Gilead Sciences is listed under Pharmaceutical Products category by Fama And French industry classification.

Gilead Sciences Leadership Team

Kathleen Watson, Executive Vice President - Human Resources
John McHutchison, Executive Vice President - Clinical Research
Andrew Cheng, Executive Vice President - HIV Therapeutics and Development Operations
John Martin, Chairman and CEO
Andrew Dickinson, Executive Vice President - Corporate Development and Strategy
Gayle Wilson, Independent Director
Daniel ODay, Chairman of the Board, CEO
Jacqueline Barton, Director
Brett Pletcher, Executive VP and General Counsel
William Lee, Executive Vice President - Research
John Madigan, Independent Director
Martin Silverstein, Executive Vice President - Strategy
Kevin Lofton, Independent Director
Paul Carter, Executive Vice President - Commercial Operations
Gregg Alton, Executive VP of Corporate and Medical Affairs and Secretary
Diana Brainard, Senior Vice President HIV and Emerging Viral Infections
Carla Hills, Independent Director
John Cogan, Lead Independent Director
John Milligan, Pres and COO
Nicholas Moore, Independent Director
James Meyers, Executive Vice President - Worldwide Commercial Operations
Katie Watson, Executive Vice President of Human Resources
Kelly Kramer, Director
Johanna Mercier, Chief Commercial Officer
Jyoti Mehra, Executive Vice President of Human Resources
Laura Hamill, Executive Vice President - Worldwide Commercial Operations
Robin Washington, CFO and Executive VP
Norbert Bischofberger, Chief Scientific Officer and Executive VP of RandD
Per WoldOlsen, Independent Director
Harish Manwani, Director
Taiyin Yang, Executive Vice President - Pharmaceutical Development and Manufacturing
Kevin Young, COO
Etienne Davignon, Independent Director
Richard Whitley, Independent Director

Stock Performance Indicators

Current Sentiment - GILD

Gilead Sciences Investor Sentiment

Majority of Macroaxis users are currently bullish on Gilead Sciences. What is your judgment towards investing in Gilead Sciences? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Please check Risk vs Return Analysis. Please also try Focused Opportunities module to build portfolios using our predefined set of ideas and optimize them against your investing preferences.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page